Masoud Etemadifar
Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan University of Medical Sciences, Isfahan, Iran
Dr. Masoud Etemadifaris awarded Doctor in Medicine (MD), Faculty of Medicine, Isfahan University of
Medical Sciences, Isfahan, Iran in 1984 - 1989. Internship, Isfahan University of medical sciences in 1989-1990. Resident of Neurology, Department of Neurology ,Isfahan University of
medical sciences in 1990-1993.He is a Professor of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran. He has been appointed as;
Director of Isfahan Multiple Sclerosis clinic, Al-Zahra Hospital, Isfahan University
of Medical Sciences, Isfahan, Iran. (2007 – present)
Director of Isfahan Multiple Sclerosis Society, Isfahan, Iran. ( 2001 – present)
Member of research council of Isfahan Neurosciences Research Center, Isfahan
University of Medical Sciences, Isfahan, Iran. (2007 – present)
Director of Al-Zahra hospital Neurology ward. (1994- present)
Director of Isfahan Epilepsy Society. (2003- present)
His Research publications includes;
1.The preventive role of topical timolol in treatment of migraine headaches. Etemadifar
M, Abedi MR. Journal of Research in Medical Sciences 2005;10 (5): 288-291.
2.Spectrophotometry of cerebrospinal fluid may facilitate the diagnosis in neurological
patients. Nematbakhsh M, Haghjoo-Javanmard S, Etemadifar M, Saboori M. Journal
of Research in Medical Sciences 2006;11 (2): 122-123.
3.Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Hamzehloo
A, Etemadifar M. Archives of Iranian Medicine 2006; 9 (2): 111-114.
4.Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting
multiple sclerosis. Etemadifar M, Janghorbani M,Shaygannejad V. Acta Neurologica
Scandinavica 2006;113 (5): 283-287.
5.Prevalence of multiple sclerosis in Isfahan, Iran. Etemadifar M, Janghorbani
M,Shaygannejad V, Ashtari F. Neuroepidemiology 2006;27 (1): 39-44 .
6.Early onset cardiotoxicity associated with mitoxantrone in patients with multiple
sclerosis. Hamzehloo A, Etemadifar M. Neurosciences 2006; 11 (3): 221-222.
7.Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.
Hamzehloo A, Etemadifar M. Archives of Iranian Medicine 2007; 10 (1): 59-64.
8.Childhood-onset multiple sclerosis: report of 82 patients from Isfahan, Iran. Arch
Iran Med. Etemadifar M, Nasr-Esfahani AH, Khodabandehlou R, Maghzi AH. 2007;
10 (2): 152-6.
9.Clinical and demographical characteristics of primary progressive multiple sclerosis
in Isfahan, Iran. Maghzi AH, Etemadifar M, Saadatnia M. Eur J Neurol.
2007;14(4):403-7.
10.Conjugal multiple sclerosis in Isfahan, Iran: a population-based study. Maghzi AH,
Etemadifar M, Shaygannejad V, Saadatnia M, Salehi M, Hassanzadeh A.
Mult Scler. 2007; 13(5):673-5.
11.Efficacy of Gabapentin in the Treatment of SUNCT Syndrome. Cephalalgia.
Etemadifar M, Maghzi AH, Ghasemi M, Chitsaz A, Kaji Esfahani M.
2008;28(12):1339-42.
12.Comparison of interferon beta products and azathioprine in the treatment of
relapsing-remitting multiple sclerosis . Etemadifar M, Janghorbani M, Shaygannejad
V. Journal of Neurology 2007;254 (12): 1723-1728.
13.Television-provoked epilepsy in children: a follow-up survey from Isfahan, Iran.
Etemadifar M, Raoufi M, Maghzi AH, Ebrahimi A, Kaji-Esfahani M, Mousavi SA.
Arch Iran Med. 2008; 11(6):649-53.
14.Acute demyelinating disorders of the central nervous system. Harris MK, Maghzi
AH, Etemadifar M, Kelley RE, Gonzalez-Toledo E, Minagar A. Curr Treat Options
Neurol. 2009; 11(1):55-63.
Multiple Sclerosis, Neuroscience
